{"filing":{"accession_number":"0001193125-26-407728","cik":"0000818033","ticker":"HRTX","company_name":"HERON THERAPEUTICS, INC. /DE/","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-23","primary_document":"hrtx-20260923.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/818033/000119312526407728/hrtx-20260923.htm"},"events":[{"id":35818,"run_id":33012,"accession_number":"0001193125-26-407728","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Heron Therapeutics entered into a multi-product Development and License Agreement with Long Grove Pharmaceuticals granting an exclusive license to import, distribute, sell and market certain products in the United States, with obligations to collaborate on development and commercialization. The agreement includes regulatory and sales-based milestone payments, royalties, and a ten-year initial term with automatic renewals. This represents a material acquisition of intellectual property rights and commercial rights that would affect a reasonable investor's assessment of the company's product pipeline and revenue potential.","company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":40011,"accession_number":"0001193125-26-407728","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Heron Therapeutics entered into a multi-product Development and License Agreement with Long Grove Pharmaceuticals granting an exclusive license to import, distribute, sell and market certain products in the United States, with obligations to collaborate on development and commercialization. The agreement includes regulatory and sales-based milestone payments, royalties, and a ten-year initial term with automatic renewals. This represents a material acquisition of intellectual property rights and commercial rights that would affect a reasonable investor's assessment of the company's product pipeline and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T21:01:36.606481+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40011,"accession_number":"0001193125-26-407728","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Heron Therapeutics entered into a multi-product Development and License Agreement with Long Grove Pharmaceuticals granting an exclusive license to import, distribute, sell and market certain products in the United States, with obligations to collaborate on development and commercialization. The agreement includes regulatory and sales-based milestone payments, royalties, and a ten-year initial term with automatic renewals. This represents a material acquisition of intellectual property rights and commercial rights that would affect a reasonable investor's assessment of the company's product pipeline and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T21:01:36.606481+00:00","company_name":"HERON THERAPEUTICS, INC. /DE/","ticker":"HRTX","filing_date":"2026-09-29"}]}